Hematology 2021: Nonmalignant

CME

Key Studies in Nonmalignant Hematology: Independent Conference Coverage of ASH 2021

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: March 01, 2022

Expiration: February 28, 2023

David Dingli
David Dingli, MD, PhD
Mark A. Schroeder
Mark A. Schroeder, MD
Sujit Sheth
Sujit Sheth, MD

Activity

Progress
1
Course Completed

References

  1. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376:429-439.
  2. Malard F, Huang X, Sim JPY. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia. 2020;34:1229-1240.
  3. Holtan SG, Ustan C, Hoeschen A, et al. Phase II results of urinary-derived human chorionic gonadotropin/epidermal growth factor as treatment for life-threatening acute GVHD. Presented at: 63rd Annual Meeting of the American Society of Hematology; December 11-14, 2021. Abstract
  4. Holtan SG, Hoeschen A, Cao Q, et al. Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor. Blood Adv. 2020;4:1284-1295.
  5. Major-Monfried H, Renteria AS, Pawarode A, et al. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018;131:2846-2855.
  6. Pratta MA, El Jurdi NH, Rashidi A, et al. Validation of amphiregulin as a monitoring biomarker during treatment of life-threatening acute GVHD: a secondary analysis of 2 prospective clinical trials. Presented at: 63rd Annual Meeting of the American Society of Hematology; December 11-14, 2021. Abstract
  7. Herrero-Beaumont G, Calatrava MJM, Castañeda S. Abatacept mechanism of action: concordance with its clinical profile. Reumatol Clin. 2012;8:78-83.
  8. Watkins BK, Tkachev V, Furlan SN, et al. CD28 blockade controls T-cell activation to prevent graft-vs-host disease in primates. J Clin Invest. 2018;128:3991-4007.
  9. Abatacept prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2021.
  10. Nahas MR, Soiffer RJ, Kim HT, et al. Phase I clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-vs-host disease. Blood. 2018;131:2836-2845.
  11. Koshy AG, Kim HT, Stroopinsky D, et al. Phase II clinical trial of abatacept for steroid-refractory chronic graft-vs-host disease. Presented at: 63rd Annual Meeting of the American Society of Hematology; December 11-14, 2021. Abstract
  12. Saidu MEB, Bonini C, Dickinson A, et al. New approaches for the treatment of chronic graft-vs-host disease: current status and future directions. Front Immunol. 2020;11:578314.
  13. Cooke KR, Luznik L, Sarantopoulos S, et al. The Biology of chronic graft-vs-host disease. Biol Blood Marrow Transplant. 2017;23:211-234.
  14. Lee SJ, Arora M, Defilipp Z, et al. Safety, tolerability, and efficacy of axatilimab, a CSF-1R humanized antibody, for chronic graft-vs-host disease after 2 or more lines of systemic treatment. Presented at: 63rd Annual Meeting of the American Society of Hematology; December 11-14, 2021. Abstract
  15. Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-vs-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21:389-401.
  16. Ellsworth P, Ma A. Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates? Hematology Am Soc Hematol Educ Program. 2021;2021:219-225.
  17. Konkle BA. Impacting inhibitor development in hemophilia A. Blood. 2017;130:1689-1690.
  18. Male C, Andersson NG, Rafowicz, et al. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica. 2021;106:123-129.
  19. Meeks SL, Batsuli G. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. Hematology Am Soc Hematol Educ Program. 2016;2016:657-662.
  20. Walsh CE, Soucie JM, Miller CH, United States Hemophilia Treatment Center Network. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol. 2015;90:400-405.
  21. Young G, Srivastava A, Kavakli K, et al. Efficacy and safety of fitusiran prophylaxis, an siRNA therapeutic, in a multicenter phase 3 study (ATLAS-INH) in people with hemophilia A or B, with inhibitors (PwHI). Presented at: 63rd Annual Meeting of the American Society of Hematology; December 11-14, 2021. Abstract
  22. Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017;377:819-828.
  23. Srivastava A, Rangarajan S, Kavakli K, et al. Fitusiran, an investigational siRNA therapeutic targeting antithrombin for the treatment of hemophilia: first results from a phase 3 study to evaluate efficacy and safety in people with hemophilia a or B without inhibitors (ATLAS-A/B). Presented at: 63rd Annual Meeting of the American Society of Hematology; December 11-14, 2021. Abstract LBA3
  24. Mahlangu JN. Bispecific antibody emicizumab for haemophilia A: a breakthrough for patients with inhibitors. BioDrugs. 2018;32:561-570.
  25. Bender MA, Adam MP, Ardinger HH, et al. Sickle cell disease. GeneReviews Internet. Seattle (WA): University of Washington, Seattle; 1993-2022.
  26. Brown RC, Cruz K, Kalfa TA, et al. FT-4202, an allosteric activator of pyruvate kinase-R, demonstrates proof of mechanism and proof of concept after a single dose and after multiple daily doses in a phase I study of patients with sickle cell disease. Presented at: 62nd Annual Meeting of the American Society of Hematology; December 5-8, 2020. Abstract
  27. Schroeder P, Fulzele K, Forsyth S, et al. Etavopivat, a pyruvate kinase activator in red blood cells, for the treatment of sickle cell disease. J Pharmacol Exp Ther. 2022;JPET-AR-2021-000743.
  28. Kalfa TA, Telen MJ, Saraf SL, et al. Etavopivat, an allosteric activator of pyruvate kinase-R, improves sickle RBC functional health and survival and reduces systemic markers of inflammation and hypercoagulability in patients with sickle cell disease: an analysis of exploratory studies in a phase I study. Presented at: 63rd Annual Meeting of the American Society of Hematology; December 11-14, 2021. Abstract
  29. Xu JZ, Conrey A, Frey I, et al. Mitapivat (AG-348) demonstrates safety, tolerability, and improvements in anemia, hemolysis, oxygen affinity, and hemoglobin S polymerization kinetics in adults with sickle cell disease: a phase I dose escalation study. Presented at: 63rd Annual Meeting of the American Society of Hematology; December 11-14, 2021. Abstract
  30. Rab MAE, Bos J, van Oirsvhot BA, et al. Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy. Blood. 2021;137:2997-3001.
  31. Xu JZ, Conrey A, Frey I, et al. Phase I multiple ascending dose study of safety, tolerability, and pharmacokinetics/pharmacodynamics of mitapivat (AG-348) in subjects with sickle cell disease. Presented at: 62nd Annual Meeting of the American Society of Hematology; December 5-8, 2020. Abstract
  32. Man Y, Goreke U, Kucukal E, et al. Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: a standardized microfluidic assessment. Blood Cells Ml Dis. 2020;83:102424.
  33. Rees DC, Williams TN, Gladwin MT, et al. Sickle-cell disease. Lancet. 2010;376:2018-2031.
  34. Heeney MM, Rees DC, De Montalembert M, et al. Initial safety and efficacy results from the phase II, multicenter, open-label SOLACE-kids trial of crizanlizumab in adolescents with sickle cell disease (SCD). Presented at: 63rd Annual Meeting of the American Society of Hematology; December 11-14, 2021. Abstract
  35. Sha N and Bhatt H. Paroxysmal nocturnal hemoglobinuria. StatPearls Internet. Treasure Island (FL): StatPearls Publishing. 2021:1-12.
  36. Jang JH, Wong LLL, Ko B-S, et al. 12-month analysis of a phase II study of iptacopan (LNP023) monotherapy for paroxysmal nocturnal hemoglobinuria. Presented at: 63rd Annual Meeting of the American Society of Hematology; December 11-14, 2021. Abstract